Philadelphia, PA (March 29, 2011) – Spondyloarthritis (SpA) is a group of inflammatory conditions causing spine and joint pain and deformity, mostly in young men. Important updates on the epidemiology, diagnosis, and treatment of SpA are presented in the April issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
The special symposium issue includes ten papers presented by a roster of international experts at last year’s Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN), held in Houston, Texas. The symposium Guest Editors are Dr. Luis R. Espinoza of the Louisiana State University Health Science Center, Dr. John D. Reveille of University of Texas-Houston Health Science Center, and Dr. Daniel O. Clegg of University of Utah School of Medicine.
How Frequent Is SpA? SPARTAN Participants Share Country-Specific Data
Spondyloarthritis is a relatively common and disabling inflammatory disease. There are several different forms of SpA, marked by destructive arthritis of the spine and other joints. Spondyloarthritis most commonly develops in adolescent boys and young men. The cause is unknown, but SpA tends to run in families. There is no cure, but effective treatments for SpA are available.
A highlight of the 2010 SPARTAN meeting was a series of presentations that help to clarify the rates and characteristics of SpA across North, South, and Central America. Based on the best available data, the overall prevalence of SpA in the United States may be over one percent of the population.
An ongoing National Health and Nutrition Examination Survey (NHANES) study will soon provide more precise estimates of the total prevalence of SpA, as well as specific subtypes-which include ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory back pain. The symposium also includes a series of reports on the epidemiology of SpA in Brazil, Argentina, Colombia, Central America, and Mexico.
New Findings on Bone Deformity, MRI Diagnosis, and More
Another article provides an in-depth look at the process of bone deformity in SpA. The bone changes in SpA appear similar to those of rheumatoid arthritis (RA), so the two diseases are often treated the same way. However, recent studies suggest that the processes triggering bone deformity in SpA differ from those in RA. Specific signaling molecules have been identified, suggesting it may be possible to develop specific treatments targeting the processes involved in SpA.
The symposium includes an update on the role of magnetic resonance imaging (MRI) in diagnosing SpA. The MRI finding of inflammation in the sacroiliac joint (the joint between the lower spine and pelvis) appears to be a particularly important sign of SpA-it’s found in a significant proportion of young patients with back pain, and even those with no symptoms of back pain or arthritis. Educational programs will be needed to help increase physician awareness of new criteria for the diagnosis of SpA, including sacroiliac joint inflammation.
Another presentation highlights the risk of infections with mycobacterial pathogens related to tuberculosis. The infections may be related to SpA treatments that compromise the immune system, or to the disease itself. Evaluation for these “nontuberculous mycobacteria” may be especially important in patients receiving modern “biologic” therapies for SpA (TNF alpha blockers).
The 2010 SPARTAN meeting “proved to be a successful and collegial exchange of information,” Drs. Espinoza, Reveille, and Clegg write in an introductory article. The SPARTAN group is a network of health care professionals dedicated to research, awareness, and treatment of SpA. Members of SPARTAN meet every year to share and disseminate the latest advances in scientific understanding and clinical management of these conditions. The next Annual Research and Education meeting will be held July 29 to 30, 2011, in Portland, Ore.
About the The American Journal of the Medical Sciences
Founded in 1820, The American Journal of the Medical Sciences (The AJMS) is the official journal of the Southern Society for Clinical Investigation. Regular features include Clinical and Basic Investigation studies, Reviews, Historical Articles, Case Reports, Images in the Medical Sciences. Other special features include Grand Round contributions from the Southwestern Internal Medicine Conference, Cardiology Grand Rounds from Vanderbilt and Emory Universities, Case Records of the VA Maryland Healthcare System/University of Maryland Medicine, and Clinical Pathological Correlation from Texas A&M Health Science/Scott & White Memorial Hospital. The AJMS publishes original articles dealing with topics such as infectious disease, rheumatology/immunology, hematology/oncology, cardiology, pulmonology/critical care, gastroenterology, nephrology, neurology and endocrinology. Website: amjmedsci.org.
About the Southern Society for Clinical Investigation
Founded in 1946, the Southern Society for Clinical Investigation (SSCI) is a regional academic society dedicated to the advancement of medically-related research. Its major focus is on encouraging students and postgraduate trainees (residents and fellows) to enter academic medicine and to support junior faculty success in clinical investigation. SSCI members are committed to mentoring future generations of medical investigators and promoting careers in academic medicine. Website: ssciweb.org.
About Wolters Kluwer Health
Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services. LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
Wolters Kluwer Health is a division of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of €3.4 billion ($4.9 billion), employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.
Contacts:
Robert Dekker
Director of Communications
Wolters Kluwer Health
+1 (215) 521-8928
Robert.Dekker@wolterskluwer.com
Connie Hughes
Director, Marketing Communications
Wolters Kluwer Health Medical Research
+1 (646) 674-6348
Connie.Hughes@wolterskluwer.com